Skip to main content

An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.

Status
recruiting
Phase
Phase 2
Institution
Charles Raison
Principal investigator
Charles Raison, MD
Start date
2025-05-13
End date
2029-05-01
Registry ID
NCT06512194

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.